{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:20:19Z","timestamp":1794442819290,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1245\/s10434-026-20017-4","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:42:36Z","timestamp":1782513756000},"page":"7881-7893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Yawen","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pereyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Podrascanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel A. Kankeu","family":"Fonkoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin B.","family":"Conboy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"3","key":"20017_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jso.70169","volume":"133","author":"RA Pereira","year":"2026","unstructured":"Pereira RA, Barcellos G, Lenz G, Pereira AAL, Biachi de Castria T. Neoadjuvant chemotherapy in resectable biliary tract cancer: a systematic review and metanalysis. J Surg Oncol. 2026;133(3):313\u20135. https:\/\/doi.org\/10.1002\/jso.70169","journal-title":"J Surg Oncol."},{"issue":"2","key":"20017_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506","journal-title":"Ann Oncol."},{"issue":"11","key":"20017_CR3","doi-asserted-by":"publisher","first-page":"106994","DOI":"10.1016\/j.ejso.2023.106994","volume":"49","author":"H Hassan","year":"2023","unstructured":"Hassan H, Chakrabarti S, Zemla T, et al. Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. Eur J Surg Oncol. 2023;49(11):106994. https:\/\/doi.org\/10.1016\/j.ejso.2023.106994","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"20017_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.amjsurg.2021.02.029","volume":"221","author":"TL Sutton","year":"2021","unstructured":"Sutton TL, Billingsley KG, Walker BS, et al. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg. 2021;221(6):1182\u20137. https:\/\/doi.org\/10.1016\/j.amjsurg.2021.02.029","journal-title":"Am J Surg."},{"key":"20017_CR5","doi-asserted-by":"publisher","first-page":"175883592412307","DOI":"10.1177\/17588359241230756","volume":"16","author":"H Taghizadeh","year":"2024","unstructured":"Taghizadeh H, Dong Y, Gruenberger T, Prager GW. Perioperative and palliative systemic treatments for biliary tract cancer. Ther Adv Med Oncol. 2024;16:17588359241230756.","journal-title":"Ther Adv Med Oncol."},{"issue":"11","key":"20017_CR6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.hpb.2025.08.001","volume":"27","author":"E Panettieri","year":"2025","unstructured":"Panettieri E, De Rose AM, Vega EA, et al. International survey on the use of preoperative chemotherapy in the setting of multimodality management of intrahepatic cholangiocarcinoma. HPB (Oxford). 2025;27(11):1418\u201326. https:\/\/doi.org\/10.1016\/j.hpb.2025.08.001","journal-title":"HPB Oxford."},{"issue":"11","key":"20017_CR7","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1245\/s10434-020-09536-w","volume":"28","author":"MC Mason","year":"2021","unstructured":"Mason MC, Massarweh NN, Tzeng CD, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol. 2021;28(11):6725\u201335. https:\/\/doi.org\/10.1245\/s10434-020-09536-w","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20017_CR8","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","volume":"28","author":"O Utuama","year":"2021","unstructured":"Utuama O, Permuth JB, Dagne G, et al. Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease. Ann Surg Oncol. 2021;28(4):1939\u201349. https:\/\/doi.org\/10.1245\/s10434-020-09478-3","journal-title":"Ann Surg Oncol."},{"key":"20017_CR9","doi-asserted-by":"publisher","first-page":"102263","DOI":"10.1016\/j.gassur.2025.102263","volume":"30","author":"A Elemosho","year":"2026","unstructured":"Elemosho A, Chatzipanagiotou OP, Angez M, Pawlik TM. Comparative efficacy of neoadjuvant chemotherapy plus surgical resection vs upfront surgery for potentially resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2026;30:102263.","journal-title":"J Gastrointest Surg."},{"issue":"8","key":"20017_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","volume":"45","author":"S Yadav","year":"2019","unstructured":"Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019;45(8):1432\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.023","journal-title":"Eur J Surg Oncol."},{"issue":"14","key":"20017_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med."},{"issue":"11","key":"20017_CR12","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","volume":"30","author":"SK Maithel","year":"2023","unstructured":"Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30(11):6558\u201366. https:\/\/doi.org\/10.1245\/s10434-023-13809-5","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"20017_CR13","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid."},{"issue":"1","key":"20017_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12957-018-1540-1","volume":"17","author":"C Wang","year":"2019","unstructured":"Wang C, Pang S, Si-Ma H, et al. Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection. World J Surg Oncol. 2019;17(1):2. Published 2019 Jan 3. https:\/\/doi.org\/10.1186\/s12957-018-1540-1","journal-title":"World J Surg Oncol."},{"issue":"9","key":"20017_CR15","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1245\/s10434-023-13636-8","volume":"30","author":"L Alaimo","year":"2023","unstructured":"Alaimo L, Lima HA, Moazzam Z, et al. Development and validation of a machine-learning model to predict early recurrence of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30(9):5406\u201315. https:\/\/doi.org\/10.1245\/s10434-023-13636-8","journal-title":"Ann Surg Oncol."},{"key":"20017_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/136518202760378489","volume":"2","author":"YY Pang","year":"2000","unstructured":"Pang YY. The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000; 2:333-39. HPB (Oxford). 2002;4(2):99\u2013100. https:\/\/doi.org\/10.1080\/136518202760378489","journal-title":"HPB."},{"issue":"2","key":"20017_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae","journal-title":"Ann Surg."},{"key":"20017_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","volume":"25","author":"YS Chun","year":"2018","unstructured":"Chun YS, Pawlik TM, Vauthey J-N. 8th Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25:845\u20137.","journal-title":"Ann Surg Oncol."},{"key":"20017_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","volume":"32","author":"TS Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32:1111\u201326.","journal-title":"Ann Oncol."},{"issue":"4","key":"20017_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11605-023-05606-y","volume":"27","author":"A Parente","year":"2023","unstructured":"Parente A, Kamarajah SK, Baia M, et al. Neoadjuvant chemotherapy for intrahepatic, perihilar, and distal cholangiocarcinoma: a national population-based comparative cohort study. J Gastrointest Surg. 2023;27(4):741\u20139. https:\/\/doi.org\/10.1007\/s11605-023-05606-y","journal-title":"J Gastrointest Surg."},{"issue":"9","key":"20017_CR21","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1007\/s00432-023-04603-7","volume":"149","author":"MN Kinzler","year":"2023","unstructured":"Kinzler MN, Jeroch J, Klasen C, et al. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center. J Cancer Res Clin Oncol. 2023;149(9):6391\u20138. https:\/\/doi.org\/10.1007\/s00432-023-04603-7","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"20017_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-020-06804-6","volume":"20","author":"B Ma","year":"2020","unstructured":"Ma B, Meng H, Tian Y, et al. Distinct clinical and prognostic implication of IDH1\/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer. 2020;20(1):318. Published 2020 Apr 15. https:\/\/doi.org\/10.1186\/s12885-020-06804-6","journal-title":"BMC Cancer."},{"issue":"3","key":"20017_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.31799","volume":"74","author":"G Kendre","year":"2021","unstructured":"Kendre G, Marhenke S, Lorz G, et al. The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion-driven cholangiocarcinoma. Hepatology. 2021;74(3):1357\u201370. https:\/\/doi.org\/10.1002\/hep.31799","journal-title":"Hepatology."},{"issue":"12","key":"20017_CR24","doi-asserted-by":"publisher","first-page":"e1734","DOI":"10.1093\/oncolo\/oyae170","volume":"29","author":"S Liu","year":"2024","unstructured":"Liu S, Weng J, Cao M, et al. FGFR2 fusion\/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma. Oncologist. 2024;29(12):e1734\u201347. https:\/\/doi.org\/10.1093\/oncolo\/oyae170","journal-title":"Oncologist."},{"issue":"5","key":"20017_CR25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/hepr.13875","volume":"53","author":"K Toshida","year":"2023","unstructured":"Toshida K, Itoh S, Yugawa K, et al. Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection. Hepatol Res. 2023;53(5):432\u20139. https:\/\/doi.org\/10.1111\/hepr.13875","journal-title":"Hepatol Res."},{"key":"20017_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet."},{"key":"20017_CR27","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","volume":"21","author":"SH Tella","year":"2020","unstructured":"Tella SH, Kommalapati A, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020;21:e29\u201341.","journal-title":"Lancet Oncol."},{"issue":"1","key":"20017_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/hepr.70031","volume":"56","author":"Y Maruki","year":"2026","unstructured":"Maruki Y, Yatabe Y, Mizoguchi C, et al. FGFR2 fusions or rearrangements in young intrahepatic and perihilar cholangiocarcinoma patients: key genetic insights from a pan-asian study. Hepatol Res. 2026;56(1):78\u201388. https:\/\/doi.org\/10.1111\/hepr.70031","journal-title":"Hepatol Res."},{"issue":"8","key":"20017_CR29","doi-asserted-by":"publisher","first-page":"e1061","DOI":"10.1093\/oncolo\/oyae132","volume":"29","author":"S Xu","year":"2024","unstructured":"Xu S, Cao L, Chen R, et al. Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. Oncologist. 2024;29(8):e1061\u201372. https:\/\/doi.org\/10.1093\/oncolo\/oyae132","journal-title":"Oncologist."},{"issue":"8","key":"20017_CR30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","volume":"127","author":"O Neumann","year":"2022","unstructured":"Neumann O, Burn TC, Allg\u00e4uer M, et al. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer. 2022;127(8):1540\u20139. https:\/\/doi.org\/10.1038\/s41416-022-01908-1","journal-title":"Br J Cancer."},{"issue":"21","key":"20017_CR31","doi-asserted-by":"publisher","first-page":"10755","DOI":"10.3390\/ijms262110755","volume":"26","author":"L Darman","year":"2025","unstructured":"Darman L, Kaurich Q, Hassan MS, von Holzen U, Awasthi N. Expanding horizons in cholangiocarcinoma: emerging targets beyond FGFR2 and IDH1. Int J Mol Sci. 2025;26(21):10755. Published 2025 Nov 5. https:\/\/doi.org\/10.3390\/ijms262110755","journal-title":"Int J Mol Sci."},{"key":"20017_CR32","doi-asserted-by":"publisher","first-page":"844800","DOI":"10.3389\/fgene.2022.844800","volume":"13","author":"C Guo","year":"2022","unstructured":"Guo C, Liu Z, Yu Y, et al. TP53 \/KRAS co-mutations create divergent prognosis signatures in intrahepatic cholangiocarcinoma. Front Genet. 2022;13:844800. Published 2022 Mar 25. https:\/\/doi.org\/10.3389\/fgene.2022.844800","journal-title":"Front Genet."},{"issue":"8","key":"20017_CR33","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","volume":"28","author":"H Verdaguer","year":"2022","unstructured":"Verdaguer H, Saur\u00ed T, Acosta DA, et al. ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma. Clin Cancer Res. 2022;28(8):1662\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2384","journal-title":"Clin Cancer Res."},{"issue":"1","key":"20017_CR34","doi-asserted-by":"publisher","first-page":"15421","DOI":"10.1038\/s41598-023-42083-4","volume":"13","author":"B Doleschal","year":"2023","unstructured":"Doleschal B, Taghizadeh H, Webersinke G, et al. Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment. Sci Rep. 2023;13(1):15421. Published 2023 Sep 18. https:\/\/doi.org\/10.1038\/s41598-023-42083-4","journal-title":"Sci Rep."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20017-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:48:28Z","timestamp":1786204108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20017-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["20017"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20017-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was a retrospective analysis that did not receive any financial support from external grants.","order":1,"name":"Ethics","label":"Financial Support Statement","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Nguyen H. Tran has received funding or has served as a consultant (directed to Mayo Clinic Foundation) for AstraZeneca, DAVA Oncology, Elevar, Exact Sciences, Exelixis, Genentech, Ipsen, and QED\/Helsinn Therapeutics. Dr. Tran\u2019s research is supported by the National Institute of Minority Health and Health Disparity K23 Career Development grant (K23MD017217-01A1). The remaining authors have no conflicts of interest.","order":2,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}